EURUSD, H4 The European Central Bank (ECB) left interest rates unchanged yesterday, but surprised by announcing the end of the APP asset purchase program in Q3, with accelerating cuts in April at 40 billion euros, 30 billion euros in May and 20 billion euros in June compared to the previous schedule of EUR 40 billion […]

TOKYO, Mar 11, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today the company will present research from its robust Alzheimer's disease (AD) pipeline, including the latest findings on lecanemab, Eisai's investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of early AD at the AD/PD 2022 International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) from March 15-20 in Barcelona, Spain and virtually.

The lecanemab data and additional research findings from Eisai's clinical development programs will be featured in 13 presentations. Lecanemab was granted Breakthrough Therapy and Fast Track designations by the U.S. Food and Drug Administration (FDA) in June and December 2021, respectively. Eisai anticipates completing lecanemab's rolling submission of a Biologics License Application for the treatment of early AD to the FDA under the accelerated approval pathway in the first quarter of Eisai's fiscal year 2022, which begins April 1, 2022. Additionally, the readout of the Phase 3 confirmatory Clarity AD clinical trial will occur in the Fall of 2022. Eisai initiated a submission to the Pharmaceuticals and Medical Devices Agency (PMDA) of application data of lecanemab under the prior assessment consultation system in Japan in March 2022.

"Four key presentations at AD/PD 2022 advance our understanding of the mechanism of action of Eisai's investigational anti- Abeta protofibril antibody lecanemab and the therapy's clinical and safety profile, including amyloid related imaging abnormalities, or ARIA, from the Phase 2b study and open-label extension, in the potential treatment of early Alzheimer's disease," said Michael Irizarry, M.D., Senior Vice President, Deputy Chief Clinical Officer, Neurology Business Group, Eisai Inc. "In addition to lecanemab, Eisai's robust pipeline includes compounds targeting the tau pathway, other pathways leading to neurodegeneration, and the testing of combination therapies that may be the optimal approach to treat or even prevent Alzheimer's disease."

The focus on AD has historically been on alleviating cognitive, functional, and behavioral symptoms, but there has been significant progress in understanding the biological mechanisms of the disease. Eisai's investigational pipeline aims to treat the range of underlying pathophysiology, including amyloid, tau and neurodegeneration.

"Because of the robust design of the lecanemab Phase 2b study, Eisai was able to design the Phase 3 confirmatory Clarity AD clinical trial to optimally verify lecanemab's clinical efficacy and safety in early Alzheimer's disease," said Ivan Cheung, Chairman, Eisai Inc., Senior Vice President, President Neurology Business Group and Global Alzheimer's Disease Officer, Eisai Co., Ltd. "Part of the recruitment strategy for the Clarity AD confirmatory trial was to ensure greater inclusion of ethnic and racial populations. While there is still important work to be done in ensuring minority populations' participation in clinical trials, Eisai is proud that approximately 25% of the total U.S. enrollment in Clarity AD consists of African American and Hispanic persons living with early Alzheimer's disease, which mirrors the U.S. Medicare population."

This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that such investigational agent will successfully complete clinical development or gain health authority approval.

For more information, visit https://www.eisai.com/news/2022/news202218.html.


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comEisai Co., Ltd. announced today the company will present research from its robust Alzheimer's disease (AD) pipeline, including the latest findings on lecanemab, Eisai's investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of early AD at the AD/PD 2022 International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) from March 15-20 in Barcelona, Spain and virtually.

TOKYO, Mar 11, 2022 - (JCN Newswire) - Mitsubishi Heavy Industries Air-Conditioning and Refrigeration Corporation (MHI-AC&R), a Group company of Mitsubishi Heavy Industries, Ltd. (MHI), has newly developed a large-capacity brine refrigeration system adopting a nitrogen (N2) refrigerant having both zero ozone depletion potential (ODP)(1) and zero global warming potential (GWP)(2). The new system can accommodate even cryotemperature needs, placing it at the pinnacle of industry offerings(3). The Company has just delivered a unit of the new system to The Honjo Chemical Corporation (Neyagawa, Osaka), a manufacturer of organic chemicals and other products, and further sales in the domestic market will be pursued going forward.
The new system can refrigerate at ultra-low and cryo-temperatures (brine temperature: -45℃ to -100℃) through application of MHI-AC&R's proprietary (patented) air refrigeration cycle technology. The unit also features one of the industry's most compact sizes, enabling easy handling and transport. Its compression expansion machine incorporates MHI Group's accumulated high technologies in gas turbines. In addition to capturing the energy generated during air expansion cooling and using it as drive power, stable operation is achieved through the integration of high technologies such as energy-saving inverter control.

The new refrigeration system contributes significantly to curbing global warming through the adoption of N2, a natural refrigerant having zero environmental impact. In recent years, initiatives to prevent climate change have accelerated in momentum. In Japan, since April 2015, when the Act on Rational Use and Appropriate Management of Fluorocarbons(4) went into effect, the low-temperature refrigeration machine market has been called on to adopt low-GWP refrigerants. Internationally, in tandem with implementation of the Kigali Amendment to the Montreal Protocol on Substances that Deplete the Ozone Layer in January 2019, along with revisions to the Vienna Convention for the Protection of the Ozone Layer, production of chlorofluorocarbon (CFC) substitutes and phased reduction in energy consumption have become mandatory.

Today, because there are few refrigerant options in the ultra-low-temperature refrigeration field, many refrigeration systems continue to use CFC refrigerants. However, demand for CFC-free refrigeration systems is steadily rising in order to mitigate impact on the environment. The refrigerant used in MHI-AC&R's new refrigeration system uses nitrogen, which accounts for approximately 78% of air content, so it is safe both to the environment and to humans. Use of a CFC-free refrigerant also eliminates the inspection procedures mandated under the Act on Rational Use and Appropriate Management of Fluorocarbons, and the new refrigerant is also exempt from the High Pressure Gas Safety Act which regulates the production of high-pressure gases and their consumption, etc. Another benefit is the adoption of magnetic bearings in the system's compression expansion machine, which eliminates the need for lubricating oil and enables a virtually unlimited service life, thereby helping to ease the user's maintenance and operating burdens.

(1) ODP is a coefficient expressing a refrigerant's ozone depletion potential compared to the previously widely used CFC-11 (trichlorofluoromethane), which is assigned a value of 1.0. The lower the ODP value, the smaller is the deleterious impact on the ozone layer.
(2) GWP is a coefficient expressing a refrigerant's global warming potential compared to CO2, which is assigned a value of 1.0. The lower the GWP, the higher is the refrigerant's environmental performance.
(3) Based on MHI-AC&R's in-house survey.
(4) The Act on Rational Use and Proper Management of Fluorocarbons is a totally revised update, carried out in April 2015, to the original Fluorocarbons Recovery and Destruction Law enacted in 2001. Under the revised legislation, commercial refrigeration condensing units and stationary refrigeration units with a refrigeration capacity exceeding 1.5 kilowatt (kW) (approx. 2HP) are required by 2025 to adopt refrigerants with a GWP below 1500 (CO2 =1).

Delivery Overview
Client and destination: The Honjo Chemical Corporation, Naoshima Organic Chemical Plant
(Naoshima-cho, Kagawa-gun, Kagawa Pref.)
Intended usage: Removal of heat of reaction produced during production of organic chemicals
Specification: Brine temperature -80degC (down to -100degC)

About MHI Group

Mitsubishi Heavy Industries (MHI) Group is one of the world's leading industrial groups, spanning energy, logistics & infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com.


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comMitsubishi Heavy Industries Air-Conditioning and Refrigeration Corporation (MHI-AC&R), a Group company of Mitsubishi Heavy Industries, Ltd. (MHI), has newly developed a large-capacity brine refrigeration system adopting a nitrogen (N2) refrigerant having both zero ozone depletion potential (ODP) and zero global warming potential (GWP).

HOUSTON and PUEBLO, Colo. — Vyripharm Enterprises, Inc. and CSU Pueblo announced today a partnership to support the creation of a comprehensive testing and certification laboratory that will provide the […]

An item from another one of my open scholarship networks. Hi Michael, Jenna Scaramanga just uploaded “Systems of Indoctrination: Accelerated Christian Education in England.” Systems of Indoctrination: Accelerated Christian Education in England  Jenna Scaramanga 2017, Doctoral thesis View Paper ▸ Download PDF ⬇ ABSTRACT Christian Education (ACE) is an individualised curriculum used in some private […]

Esports production company and tournament organiser BLAST has appointed Charlotte Kenny, formerly of Club Affairs, as Managing Director for its BLAST Premier CS:GO esports series. Kenny’s new role includes leading BLAST Premier’s growth and delivery as the company looks to maintain and enhance production, tournament operations, approach to fan engagement and its commercial portfolio. RELATED: […]

Reliability physics analysis can shorten the qualification process when forced to swap components or suppliers.

The post Mitigating Electronics Reliability Concerns During The Global Parts Shortage Crisis appeared first on Semiconductor Engineering.

Oil prices stay firm Oil prices remained firm overnight, finishing around 4.0% higher for the day after President Biden announced a unilateral ban on Russian energy imports. The move was well telegraphed, with oil markets having already moved higher this week in anticipation. What stopped any further squeeze was the entirely sensible decision by Europe […]

The crypto market is in red, but Waves in on fire. In about two weeks, the Ukrainan-origin token has surged 2x its price.

Prescribers, Pharmacists and Hubs Are Leveraging Surescripts Enhanced Technology to Improve Efficiency and Speed Time to Therapy ARLINGTON, Va.–(BUSINESS WIRE)–#healthIT–In 2021, Surescripts expanded its specialty medications solutions to enable more prescribers, pharmacists and patients to benefit from the accelerated speed to therapy these innovations support. By deepening its clinical intelligence capabilities and expanding disease states […]

The post Surescripts Innovations Help Patients Get Started on Specialty Medications Faster appeared first on Fintech News.

DENTSPLY SIRONA Inc. announced that it has entered into an accelerated share repurchase agreement with Bank of America, National Association to repurchase $150 million of its common stock.

Google agreed to acquire cybersecurity company Mandiant Inc. for $5.4 billion, its second-biggest deal ever. With Mandiant, Alphabet Inc.’s Google gets more tools to protect its cloud clients by responding quickly to online threats. The company is working to recruit and support cloud customers amid stiff competition from Microsoft Corp. and Amazon.com Inc. Google will […]